CVA Family Office’s Novavax NVAX Stock Holding History

CVA Family Office’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14	Closed	-$2K	–	914
2021 Q3	$2K	Buy	+14	New	+$3.08K	﹤0.01%	346
2020 Q4	–	Sell	-14	Closed	-$2K	–	370
2020 Q3	$2K	Hold	14	–	–	﹤0.01%	346
2020 Q2	$1K	Buy	+14	New	+$535	﹤0.01%	314

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CVA Family Office's NVAX Position: Q4 2021 in Review

CVA Family Office sold out of Novavax (NVAX) in Q4 2021, closing a stake of 14 shares — an estimated $2K sold.

CVA Family Office first reported a position in NVAX in Q2 2020 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

CVA Family Office reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
CVA Family Office sold 14 Novavax shares in Q4 2021, an estimated $2K.
CVA Family Office first reported a position in Novavax in Q2 2020 and held it in 3 quarters.
CVA Family Office's Novavax position peaked at $2K in Q3 2021.
429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on CVA Family Office's 13F filing for Q4 2021, filed 25 Jan 2022.